2023 International Congress Archives - Page 173 of 186

Laryngeal clinical biomarkers in atypical Parkinsonism – results from an international multicenter study

F. Gandor, A. Vogel, L. Berger, D. Gruber, I. Claus, P. Corelli, G. Giannini, N. Madetko-Alster, G. Höglinger, M. Klietz, C. Schrader, B. Falkenburger, T. Shimohata, K. Kunieda, J. Kassubek, R. Kassubek, MJ. Marti, G. Wenning, A. Fanciulli, C. Pototschnig, T. Gurevich, Y. Manor, HJ. Kim, D. Weise, P. Urban, R. Dziewas, T. Warnecke (Beelitz-Heilstätten, Germany)
Late Onset Cerebellar Ataxia in a Patient with a Heterozygous Pathogenic KIF1A Mutation: A Case Report

D. Sell, K. Minks, D. Sirica, P. Morrison (Rochester, USA)
Late onset cerebellar ataxia in patients treated with VIM DBS

C. Héraud, C. Alecu, D. Fontaine, A. Leplus, C. Giordana (NICE, France)
Late-onset cerebellar ataxia revealing a Pantothenate-kinase-associated neurodegeneration

S. Laroussi, S. Sakka, S. Daoud, N. Bouattour, K. Moalla, N. Farhat, M. Damak, C. Mhiri (Sfax, Tunisia)
Learnings from inaugural year of foundation sponsored genetic counseling and testing program for Spinocerebellar Ataxia (SCA) types 1, 2, and 3

K. Trace, N. Beck, L. Moore (Minneapolis, USA)
Left hemisphere theta coherence between cortex and STN increases during speech

A. Nakhmani, R. Smith, V. Del Bene, M. Nelson, J. Olson, S. Brinkerhoff, Z. Irwin, J. Bentley, R. Knight, H. Walker (Birmingham, USA)
Leveraging MRI and machine-learning for early detection of cognitive impairment in Parkinson’s disease

L. Saadatpour, A. Vijayakumari, B. Walter, H. Fernandez (Cleveland, USA)
Levodopa Carbidopa Intestinal Gel for Parkinson’s Disease over 11 years: A Single Center “Real-World” Experience

C. Vekhande, M. Hamed, G. Tremain, J. Mah, A. Shetty, A. Lazarescu, O. Suchowersky (Edmonton, Canada)
Levodopa-carbidopa intestinal gel for managing severe refractory tremors of idiopathic Parkinson’s disease: Case Series

M. Abu Al-Melh, N. Abdelall, T. Al-Otaibi (Ahmadi governorate, Kuwait)
Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience

V. Constantin, S. Szatmari, K. Orban-Kis, S. Bataga, R. Neagoe, M. Ciorba, I. Mihaly, K. Kelemen, J. Szasz (Targu Mures, Romania)
Levodopa-entacapone-carbidopa intestinal gel infusion for Parkinson’s disease: An analysis of data collected from the Swedish national register of Parkinson’s disease.

M. öthman, P. Odin, F. Bergquist, A. Johansson, R. Constantinescu, M. Scharfenort, H. Widner, D. Nyholm (Uppsala, Sweden)
Levodopa-entacapone-carbidopa-infusion treatment in Parkinson’s disease: A six-month follow-up study

V. Viljaharju, T. Mertsalmi, KAM. Pauls, M. Koivu, J. Eerola-Rautio, M. Udd, E. Pekkonen (Helsinki, Finland)
Levodopa-induced dyskinesia and Huntington’s chorea: link to current motor control theories

JF. Daneault, Y. Liu, J. Miranda, C. Duval, M. Chen, S. Lee (Newark, USA)
Levodopa-induced orthostatic hypotension in a large cohort of patients with Parkinson’s disease undergoing an acute levodopa challenge test

X. Wang, S. Mei, C. Han, P. Chan (Beijing, China)
Levodopa-induced orthostatic hypotension in parkinsonism: a red flag of autonomic failure

I. Cani, P. Guaraldi, G. Giannini, L. Sambati, G. Barletta, P. Cortelli, G. Calandra-Buonaura (Bologna, Italy)
Linking volume of tissue activated to neural oscillations in deep brain stimulation

A. Kutuzova, C. Graef, B. Lonergan, Y. Tai, S. Haar (London, United Kingdom)
Living with Parkinson’s disease scale: First validation study among English-speaking population

L. Ambrosio, K. Hislop-Lennie, N. Serrano-Fuentes, C. Driessens, MC. Portillo (Southampton, United Kingdom)
Local field potential changes by the patient’s conditions; 1-year follow-up of adaptive deep brain stimulation in the real world.

H. Kamo, G. Oyama, M. Ito, H. Iwamuro, A. Umemura, N. Hattori (Tokyo, Japan)
local field potential differences in stn subregion during performance of a conflict task in humans with parkinson’s disease

J. Bowersock, J. Neimat, A. Alhourani, T. Stewart, S. Wylie, N. van Wouwe (Flagstaff, USA)
Local field potentials can guide programming of Deep Brain Stimulation in Parkinson’s Disease

B. Seegmiller, P. Coss (San Antonio, USA)
Local field potentials in the subthalamic nucleus of patients with Parkinson’s disease – Effect of the deep brain stimulation

S. Taguchi, T. Nakura, H. Saiki, S. Miyachi, M. Doyu (Nagakute, Japan)
Localisation of distinct brain networks in premanifest and manifest Huntington’s disease

E. Younger, E. Ellis, J. Joutsa, D. Corp (Burwood, Australia)
Localizing a brain network of progressive supranuclear palsy

E. Ellis, J. Morrison-Ham, E. Younger, J. Joutsa, D. Corp (Melbourne, Australia)
London-Dhaka Parkinson’s Cognition Study: A collaboration to evaluate cognitive impairment in under-represented Parkinson’s disease patients

T. Zannat, K. Dey, A. Zirra, A. Haque, E. Camboe, T. Haque, S. Waters, D. Mair, C. Marshall, A. Noyce, A. Habib (Dhaka, Bangladesh)
Loneliness, Self-Efficacy, and Resilience: Neglected Modifiable Contributors to Parkinson’s Disease Symptom Severity and Quality of Life

I. Subramanian, B. Mcdaniels, D. Fox, L. Mischley (Los Angeles, USA)
Long duration response to levodopa in advanced Parkinson disease

P. Nieto, A. García, I. Martín, R. Ibañez, JP. Cabello, J. Vaamonde (Ciudad Real, Spain)
Long term effects of Deep Brain Stimulation on Camptocormia in Parkinson’s disease

L. Nessis, C. Oehlwein, M. Oehlwein, W J. Schulz-Schaeffer (Homburg
Long term treatment with botulinum neurotoxin for focal dystonia – effect of dose and dilution

D. Weise, P. Henn, C. Weise (Stadtroda, Germany)
Long-term dementia prevalence in Parkinson disease: Glass half-full?

J. Gallagher, J. Fedler, C. Gochanour, R. Dobkin, D. Aarsland, R. Alcalay, M. Barrett, C. Caspell-Garcia, R. Cho, L. Chahine, A. Chen-Plotkin, C. Coffey, N. Dahodwala, J. Eberling, A. Espay, J. Leverenz, I. Litvan, E. Mamikonyan, J. Morley, I. Richard, L. Rosenthal, A. Siderowf, T. Simuni, M. York, A. Willis, S. Xie, D. Weintraub (Philadelphia, USA)
Long-term effectiveness of adjuvant treatment with catechol-o-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists in Parkinson’s disease uncontrolled by levodopa: final results of the PD MED LATER randomized clinical trial

C. Clarke, C. Rick, S. Patel, R. Wooley, N. Rowland, J. Futterer, R. Ottridge, C. Jenkinson, R. Gray (Birmingham, United Kingdom)
Long-term effects of a mobile technology-based brisk walking program on Parkinsonian symptoms in Parkinson’s disease – a randomized controlled trial

MKY. Mak, ISK. Wong-Yu (Hong Kong SAR, China)
Long-term evolution of advanced Parkinson’s disease burden: second interim results from the international PROSPECT observational study

P. Sanchez Alonso, O. de Fabregues, A. Lehn, T. Oeda, F. Ory-Magne, D. Safarpour, L. Bergmann, P. Kukreja, K. Onuk, V. Fung (Majadahonda, Spain)
Long-term follow up of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration Syndrome: two case reports

D. Damas, I. Carvalho, S. Caldeira, P. Monteiro, R. Pereira, I. Cunha, F. Moreira (Coimbra, Portugal)
Long-term outcomes after subthalamic nucleus deep brain stimulation (STN-DBS) in patients with Parkinson’s Disease (PD) in Singapore

YZ. Cai, W. Li, Y. Zheng, A. Zhan, HL. Ng, Z. Xu, KY. Tay, WL. Au, L. Tan, WH. Ng, KR. Wan, S. Neo (Singapore, Singapore)
Long-term outcomes of deep brain stimulation for VPS16-related dystonia: A multi-center international study

T. Svorenova, LM. Romito, E. Mulroy, L. Cif, E. Moro, KE. Zeuner, S. Zittel, JN. Petry-Schmelzer, M. Ostrozovicova, V. Han, V. Magocova, K. Knorovsky, A. Kollova, B. Garavaglia, N. Golfrè-Andreasi, C. Reale, A. Mazzoni, A. Kaymak, G. Zorzi, R. Eleopra, V. Levi, T. Foltynie, P. Limousin, H. Akram, L. Zrinzo, F. Magrinelli, D. Murphy, H. Houlden, MA. Kurian, C. Baiata, S. Paschen, K. Lohmann, J. Volkmann, W. Hamel, MT. Barbe, R. Jech, P. Havrankova, J. Winkelmann, M. Zech, M. Skorvanek (Košice, Slovakia)
Long-term safety and durability of effect of ecopipam in pediatric patients with Tourette Syndrome: Results of a 12-month open-label extension (OLE) study

D. Gilbert, D. Kim, M. Miller, S. Horine, K. Saljooqi, G. Karkanias, S. Wanaski, T. Cunniff (Cincinnati, USA)
Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson’s disease

J. Lin, R. Ou, C. Li, Q. Wei, Y. Hou, L. Zhang, K. Liu, Q. Jiang, T. Yang, Y. Xiao, D. Pang, Y. Yu, B. Zhao, X. Chen, W. Song, J. Yang, Y. Wu, H. Shang (Chengdu, China)
Longitudinal association of mild behavioral impairment with cognitive decline in Parkinson’s disease

G. Pinilla-Monsalve, M. Kibreab, N. Maarouf, I. Kathol, Z. Ismail, O. Monchi (Montréal, Canada)
Longitudinal brain volume decline in PD with RBD and olfactory dysfunction

K. Kawabata, E. Bagarinao, K. Seppi, W. Poewe (Innsbruck, Austria)
Longitudinal change in clinical characteristics of LRRK2 carriers in a remote cohort

S. Lettenberger, P. Auinger, R. Wilson, E. Hartman, M. Pawlik, M. Khokhar, E. Dorsey, B. Valdovinos, S. Sharma, R. Holloway, C. Tanner, R. Alcalay, R. Schneider (Rochester, USA)
Longitudinal changes in brain networks associated with clinical symptoms in idiopathic rapid eye movement sleep behavior disorder

N. Wakasugi, T. Takamura, M. Abe, Y. Mukai, N. Nishikawa, T. Hatano, Y. Shimo, K. Ikenaka, H. Kadotani, Y. Sumi, N. Sawamoto, H. Watanabe, H. Mochizuki, N. Hattori, M. Katsuno, Y. Takahashi, R. Takahashi, T. Hanakawa (Tokyo, Japan)
Longitudinal clinical and biomarker characteristics of non-manifest GBA1 N409S carriers: the PPMI cohort

P. Gonzalez-Latapi, D. Harvell, T. Simuni, K. Merchant, M. Brumm, R. Alcalay, H. Cho, C. Caspell-Garcia, C. Gochanour, C. Coffey, K. Marek (Chicago, USA)
Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease

R. Miller, A. Li, M. Campbel, J. Perlmutter, P. Kotzbauer (St. Louis, USA)
Longitudinal follow-up of pure autonomic failure with cardiac sympathetic denervation: Relevance to the body-first theory of Parkinson’s disease

T. Fay Karmon, S. Hassin-Baer, Z. Shabtai, E. Druker, A. Leibowitz, Y. Sharabi (Petach Tikva, Israel)
Longitudinal free-water changes in dementia with Lewy bodies

S. Chiu, R. Chen, W. Wang, M. Armstrong, B. Boeve, K. Kantarci, D. Vaillancourt (Gainesville, USA)
Longitudinal imaging of regional volumes, presynaptic terminals and glucose metabolism in brains of people with early Huntington’s disease

A. Delva, K. van Laere, W. Vandenberghe (Leuven, Belgium)
Longitudinal recordings of subthalamic local field potentials show intra-subject consistency of beta-based physiomarkers in Parkinson’s Disease

M. Stam, B. van Wijk, A. Buijink, D. Piña-Fuentes, R. de Bie, R. Schuurman, M. Beudel (Amsterdam, Netherlands)
Low Beta-Band Suppression as a Tool for DBS Contact Selection for Akinetic-rigid Symptoms in Parkinson’s Disease

J. Strelow, T. Dembek, J. Baldermann, P. Andrade, V. Visser-Vandewalle, M. Barbe (Cologne, Germany)
Low serum vitamin E in a genetically confirmed Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)

D. Al-Shorafat, K. Al-Hayk, M. Qawasmeh, W. Kamel, S. Bashayreh (Irbid, Jordan)
Low Vision Occupational Therapy for Parkinson’s Disease – A Pilot Study at the University of Alabama at Birmingham

C. Parker, M. Maher, J. Vice, L. Lieb, M. Dean (BIRMINGHAM, USA)
LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia

K. Badanjak, P. Mulica, M. Tziortziou, S. Delcambre, S. Smajic, C. Venegas, M. Ali, T. Rolova, J. Koistinaho, P. Seibler, S. Cowley, J. Trinh, S. Pereira, P. Antony, E. Glaab, A. Grünewald (Esch-sur-Alzette, Luxembourg)
LRRK2 G2019S mutation in Multiple System Atrophy, a case report

T. Carrer, G. Bonato, M. Sandre, A. Emmi, A. Antonini (Padova, Italy)
LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α-synuclein through NF-κB pathway

JY. Liu, KJ. He, JB. Zhang, F. Wang, CF. Liu (Suzhou, China)
LRRK2 Inhibition by BIIB122/DNL151 Demonstrates Robust Target and Lysosomal Engagement: Pharmacokinetics, Pharmacodynamics and Safety in Phase 1 and Phase 1b Studies in Healthy and Parkinson’s Participants

S. Dhuria, P. Roychowdhury, H. Wong, S. Huntwork-Rodriguez, H. Solanoy, M. Goo, R. Maciuca, O. Mabrouk, K. Fraser, K. Scearce-Levie, D. Graham, D. Jennings, M. Troyer (South San Francisco, USA)
LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte‐derived macrophages and SH-SY5Y

T. Usenko, K. Basharova, A. Bezrukova, A. Izyumchenko, M. Nikolaev, G. Baydakova, S. Pavlova, E. Grigorieva, S. Medvedev, E. Zakharova, S. Zakian, S. Pchelina (Gatchina, Russian Federation)
LRRK2 PROTAC® degrader molecules induce robust biomarker responses in preclinical in vivo pharmacology studies following acute and chronic oral dosing

J. Meredith Jr, K. Kelly, V. Guss, A. Desantis, L. Kimmel, S. Soletsky, J. Pizzano, G. Cadelina, J. Chavez, S. Sparks, A. Cacace (New Haven, USA)
Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease

S. Lucas-Del-Pozo, G. Uras, F. Fierli, AHV. Schapira (London, United Kingdom)